FDA approval to initiate pivotal IDE clinical study of CERAMENT®|G* in USA

Paper in Nature Scientific Reports demonstrates the potential of the CERAMENT® drug-eluting platform. Publication entitled 'A Biphasic Calcium Sulphate Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone' (Raina, D et al).

Publication in The Bone and Joint Journal demonstrates the utility of CERAMENT®|G in the management of chronic osteomyelitis. Paper entitled 'Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite - A prospective series of 100 cases' (McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96).


Richard Davies appointed as CEO


FY 2016 sales of SEK 105m (70% YoY growth)